Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Medistim ASA (MEDI.OL)
Oslo, NO
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in a single system for vascular surgery; MiraQ Ultimate that combines TTFM and ultrasound imaging in a single system for cardiac, vascular, and transplant surgery; and imaging probes for intraoperative use. It also provides QuickFit TTFM probes, which are designed to hold the vessel and ensure precise measurements on various types of vessel grafts; Vascular TTFM probes for locking slide mechanism designed to secure the vessel while minimizing the manipulation; ultrasound imaging probes; and Doppler probes that are used to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, the company distributes and sells third party medical equipment. Medistim ASA was founded in 1984 and is headquartered in Oslo, Norway.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.33% | +0.00% | -1.72% | +12.87% | -8.06% | -12.64% | +8.57% | -18.86% | -17.84% | +338.46% | +2,113.59% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%+24.4% ★ Q1'26: +11.1% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+53.6% ★ Q1'26: -7.2% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+19.3% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+28.0% ★ Q1'26: +28.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+45.6% ★ Q1'26: +52.0% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%-0.2% ★ Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.34× ★ Q1'26: 0.18× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2007 actual |
Dec 2008 actual |
Dec 2009 actual |
Dec 2010 actual |
Dec 2011 actual |
Dec 2012 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
126.85M
est: 127.36M (-0.4%)
|
140.29M
est: 140.00M (+0.2%)
|
156.87M
est: 159.86M (-1.9%)
|
156.80M
est: 157.32M (-0.3%)
|
159.62M
est: 166.46M (-4.1%)
|
181.97M
est: 174.58M (+4.2%)
|
249.97M
est: 214.86M (+16.3%)
|
262.67M
est: 275.96M (-4.8%)
|
296.05M
est: 298.20M (-0.7%)
|
323.01M
est: 313.01M (+3.2%)
|
356.91M
est: 371.84M (-4.0%)
|
356.21M
est: 359.04M (-0.8%)
|
417.82M
est: 431.12M (-3.1%)
|
486.26M
est: 477.26M (+1.9%)
|
521.11M
est: 525.64M (-0.9%)
|
562.60M
est: 553.50M (+1.6%)
|
699.77M
est: 692.67M (+1.0%)
|
765.67M
754.94M – 776.39M
+10.5% YoY
|
833.67M
819.28M – 848.06M
+8.9% YoY
|
876.00M
862.25M – 889.75M
+5.1% YoY
|
| EBITDA |
23.89M
est: 18.83M (+26.8%)
|
26.76M
est: 23.96M (+11.7%)
|
51.44M
est: 32.91M (+56.3%)
|
29.83M
est: 48.88M (-39.0%)
|
27.58M
est: 50.28M (-45.2%)
|
47.93M
est: 52.73M (-9.1%)
|
66.81M
est: 66.20M (+0.9%)
|
65.60M
est: 43.76M (+49.9%)
|
80.39M
est: 68.20M (+17.9%)
|
86.34M
est: 96.45M (-10.5%)
|
109.74M
est: 114.57M (-4.2%)
|
111.74M
est: 110.63M (+1.0%)
|
132.03M
est: 126.35M (+4.5%)
|
163.77M
est: 138.37M (+18.4%)
|
155.10M
est: 162.19M (-4.4%)
|
155.59M
est: 170.79M (-8.9%)
|
221.03M
est: 213.73M (+3.4%)
|
236.26M
232.95M – 239.57M
+10.5% YoY
|
257.24M
252.80M – 261.68M
+8.9% YoY
|
270.30M
266.06M – 274.55M
+5.1% YoY
|
| EBIT |
22.68M
est: 13.68M (+65.8%)
|
32.52M
est: 21.99M (+47.9%)
|
47.68M
est: 27.86M (+71.1%)
|
33.60M
est: 28.05M (+19.8%)
|
22.33M
est: 43.37M (-48.5%)
|
41.65M
est: 45.48M (-8.4%)
|
56.17M
est: 57.10M (-1.6%)
|
56.36M
est: 40.15M (+40.4%)
|
65.47M
est: 61.57M (+6.3%)
|
75.00M
est: 83.19M (-9.8%)
|
91.48M
est: 98.82M (-7.4%)
|
95.48M
est: 95.64M (-0.2%)
|
114.66M
est: 114.58M (+0.1%)
|
146.43M
est: 134.18M (+9.1%)
|
131.44M
est: 140.99M (-6.8%)
|
131.08M
est: 148.47M (-11.7%)
|
196.20M
est: 185.80M (+5.6%)
|
205.38M
202.50M – 208.25M
+10.5% YoY
|
223.62M
219.76M – 227.48M
+8.9% YoY
|
234.97M
231.28M – 238.66M
+5.1% YoY
|
| Net Income |
28.39M
est: 22.71M (+25.0%)
|
13.54M
est: 31.22M (-56.6%)
|
27.87M
est: 15.41M (+80.8%)
|
18.66M
est: 27.46M (-32.1%)
|
15.49M
est: 22.31M (-30.6%)
|
30.25M
est: 23.42M (+29.1%)
|
40.42M
est: 35.53M (+13.8%)
|
39.10M
est: 26.04M (+50.2%)
|
47.57M
est: 42.72M (+11.4%)
|
57.06M
est: 47.95M (+19.0%)
|
70.31M
est: 75.23M (-6.5%)
|
69.39M
est: 72.76M (-4.6%)
|
90.90M
est: 96.40M (-5.7%)
|
113.97M
est: 115.71M (-1.5%)
|
103.82M
est: 102.54M (+1.3%)
|
103.83M
est: 109.20M (-4.9%)
|
159.21M
est: 145.78M (+9.2%)
|
155.00M
152.94M – 167.27M
+6.3% YoY
|
174.00M
169.41M – 188.44M
+12.3% YoY
|
194.50M
178.19M – 199.58M
+11.8% YoY
|
| SGA |
37.67M
est: 36.14M (+4.2%)
|
42.37M
est: 41.44M (+2.2%)
|
51.70M
est: 48.41M (+6.8%)
|
51.16M
est: 50.88M (+0.6%)
|
—
est: 20.59M (-100.0%)
|
16.28M
est: 21.60M (-24.6%)
|
20.52M
est: 27.12M (-24.3%)
|
22.31M
est: 93.23M (-76.1%)
|
44.98M
est: 103.99M (-56.7%)
|
26.54M
est: 108.57M (-75.6%)
|
28.41M
est: 46.93M (-39.5%)
|
27.03M
est: 45.31M (-40.4%)
|
32.57M
est: 54.41M (-40.1%)
|
39.54M
est: 184.85M (-78.6%)
|
150.20M
est: 73.38M (+104.7%)
|
60.56M
est: 77.27M (-21.6%)
|
99.96M
est: 96.69M (+3.4%)
|
106.88M
105.39M – 108.38M
+10.5% YoY
|
116.38M
114.37M – 118.38M
+8.9% YoY
|
122.29M
120.37M – 124.21M
+5.1% YoY
|
| EPS |
1.51
est: 1.03 (+47.3%)
|
0.76
est: 0.95 (-20.3%)
|
1.51
est: 1.61 (-6.0%)
|
1.02
est: 1.05 (-2.9%)
|
0.85
est: 1.22 (-30.6%)
|
1.66
est: 1.29 (+29.2%)
|
2.23
est: 1.94 (+14.9%)
|
2.15
est: 2.52 (-14.8%)
|
2.62
est: 2.71 (-3.3%)
|
3.14
est: 2.62 (+19.9%)
|
3.87
est: 4.11 (-5.8%)
|
3.81
est: 3.97 (-4.1%)
|
4.99
est: 5.26 (-5.2%)
|
6.25
est: 5.81 (+7.5%)
|
5.67
est: 5.61 (+1.1%)
|
5.67
est: 5.98 (-5.1%)
|
8.71
est: 7.98 (+9.2%)
|
8.76
8.37 – 9.15
+9.8% YoY
|
9.79
9.27 – 10.31
+11.8% YoY
|
10.34
9.75 – 10.92
+5.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-07 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-06 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-05 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-05-04 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-30 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-29 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-28 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-27 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-24 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.00% | 141.5K | 0.39% |
| 2 | Dimensional International Sustainability Core 1 ETF DFSI | 0.00% | 22.3K | 0.24% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 120.3K | 0.28% |
| 4 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 116.6K | 0.22% |
| 5 | Dimensional - International Core Equity Market ETF DFAI | 0.00% | — | 0.18% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Kari Eian Krogstad | Chief Executive Officer & President | 5M | female |
| Mike Karim | Chief Commercial Officer | 3M | male |
| Thomas Jakobsen | Chief Financial Officer | 2M | male |
| Roger Reino Morberg | Vice President of Sales - APAC | 2M | male |
| Hæge Johanne Krogh Wetterhus | Vice President of Marketing | 2M | female |
| Hakon Grothe | Chief Innovation Officer | 2M | male |
| Ole Arne Eiksund | Chief Business Development Officer | 2M | male |
| Ole Jorgen Robsrud | Managing Director of 3rd party distribution | 2M | male |
| Stephanie D'Avout Stenhagen | Vice President of Sales EMEA | 2M | female |
| Helge Borslid | Vice President of Operations | 2M | male |
| Monica Weiseth | Vice President of QA\Reg | 558.9K | — |
| Jonas Tysso | Chief R&D Officer | 551.6K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MEDI.OL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
